{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-325370","form_type":"8-K","ticker":"SYBX","cik":"0001527599","company_name":"SYNLOGIC, INC.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.864791+00:00","generated_at":"2026-06-28T09:52:41.495290+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Synlogic reports Q3 net loss $16M; PKU Phase 2 shows proof of concept, moving to Phase 3","bullets":["Interim Phase 2 SynPheny-1 data: SYNB1618 achieved proof of concept with statistically significant Phe reduction in PKU patients.","SYNB1934 showed 2x improvement in Phe metabolism biomarkers vs SYNB1618; Phase 3 start planned in 2022.","Cash, equivalents and short-term investments $150.1M as of Sept 30, 2021; net proceeds $48.4M from public offering.","Revenue $0.9M from Roche IBD collaboration; first milestone payment earned; no further SYNB1891 studies planned.","Net loss $16.0M ($0.29/share) vs $13.2M ($0.36/share) in Q3 2020; R&D expense $13.4M, G&A $3.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-325370","json":"https://secwatch.observer/filing/0001193125-21-325370.json","markdown":"https://secwatch.observer/filing/0001193125-21-325370.md","text":"https://secwatch.observer/filing/0001193125-21-325370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527599/000119312521325370/0001193125-21-325370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527599/000119312521325370/d259422d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:52:41.495290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}